linjc16/ctgov huggingface dataset:
Awareness of Chinese National Adult Lipid Treatment Guideline (2007) and Rate of Patients Achieving the Treatment Goal

Study Overview
=================
Brief Summary
-----------------
This study is designed to survey the awareness rate of Chinese National Adult Lipid Treatment Guideline (2007) by cardiologists; To survey the control rate of the patients with dyslipidemia in real world; and to evaluate the percentage of hyperlipidemia patients who achieved target LDL-C level according to the Chinese National Adult Lipid Treatment Guideline (2007) following 8-week treatment by Crestor® 5mg or 10mg

Official Title
-----------------
A Cross-sectional Study to Survey the Awareness of Chinese National Adult Lipid Treatment Guideline (2007) and the Rate of Patients (on Treatment) Achieving the Hyperlipidaemia Treatment Goal With Crestor 5mg to 10mg for 8 Weeks

Conditions
-----------------
Hyperlipidemia

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosed as dyslipidemia by doctors Having lipids test and record within one months Diagnosed as hypercholesterolemia or mixed dyslipidaemias and has been prescribed Crestor® 5mg or 10mg Exclusion Criteria: Unable or unwilling to provide the Inform Consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1<br>patients being diagnosed as dyslipidemia but not receiving Crestor® | |
| 2<br>hypercholesterolemia or mixed dyslipidemia and have been initiated treatment with Crestor® | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| the awareness rate of Chinese National Adult Lipid Treatment Guideline (2007) by cardiologists |  | 1 time | 
| the control rate of patients reaching target LDL-C level |  | 8 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| the percent change from baselines in TC, TG, HDL-C |  | 8 weeks | 
| the percentage of hyperlipidemia patients in different risk categories who achieved target LDL-C level according to the Chinese National Adult Lipid Treatment Guideline (2007) |  | 8 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Hyperlipidemia, Chinese National Adult Lipid Treatment Guideline (2007), Crestor®
Safety and Efficacy of the Novel Selective Nicotinic Receptor Partial Agonist, CHANTIX (Varenicline) in Patients With Acute Coronary Syndrome

Study Overview
=================
Brief Summary
-----------------
Assess the role of a nicotine antagonist in helping patients presenting to hospital with acute coronary syndrome to stop smoking.

Official Title
-----------------
Safety and Efficacy of the Novel Selective Nicotinic Receptor Partial Agonist, CHANTIX (Varenicline) in Patients With Acute Coronary Syndrome

Conditions
-----------------
Smoking, Acute Coronary Syndrome

Intervention / Treatment
-----------------
* Drug: Varenicline 100 mg by mouth twice daily
* Drug: control


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: active smokers presenting to hospital with an acute coronary syndrome Exclusion Criteria: patients with an acute coronary syndrome who are not active smokers

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: active Chantix<br>active drug to help smoking cessation | Drug: Varenicline 100 mg by mouth twice daily<br>* this is an active drug to help smoking cessation<br>|
| Placebo Comparator: sugar pill<br> | Drug: control<br>* this is the placebo that will help us maintain a blinded study<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| nicotine levels |  | 1 month | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| recurrent myocardial ischemia |  | 1 month | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
smoking, tobacco abuse
Bone Loss in Men on Androgen Blockade as Adjuvant Therapy for Prostate Cancer

Study Overview
=================
Brief Summary
-----------------
Patients with advanced prostate cancer undergoing adjuvant treatment with androgen blockade will be followed over a 1 year interval to assess the effects of this treatment on bone metabolism. It is expected that men undergoing androgen blockade will experience accelerated bone loss.

Official Title
-----------------
Bone Loss in Men on Androgen Blockade as Adjuvant Therapy for Prostate Cancer

Conditions
-----------------
Prostate Cancer, Bone Loss

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Men Age of 40 years or greater Diagnosis of advanced prostate cancer (ie: prostate-specific antigen [PSA] less than 25 ug/L and undergoing continued treatment with leuteinizing hormone-releasing hormone [LHRH] therapy) Willing and able to consent Exclusion Criteria: Metastatic disease to bone Medications affecting bone turnover (bisphosphonate, steroids, anticonvulsant) Renal failure (serum creatinine > 200 umol/L) Co-morbidity factors affecting bone density (ie: Paget's, rheumatoid arthritis) Factors affecting ability to perform the bone density tests using femoral head measurements (ie: bilateral hip arthroplasty) Cancer other than skin, except when, in the investigators' opinion, it is determined to be appropriate and not adversely affect the outcome of the trial Gastrointestinal (GI) pathology (eg. malabsorption syndrome) Parathyroid disease

Ages Eligible for Study
-----------------
Minimum Age: 40 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Thyromental Height Test as a Predictor of Difficult Airway:

Study Overview
=================
Brief Summary
-----------------
Anesthesia is increasingly safe. Major complications of airway management are no more common but still the most life-threatening condition amongst anesthesia practice and even medicine. Thyromental height test (TMHT) is an objective measure of the height between the anterior borders of the mentum and thyroid cartilage, measured while the patient is lying supine with the mouth closed. This study was designed to assess the validity of the TMHT as a single objective predictor for difficult laryngoscopy and to be compared to other objective measures.

Official Title
-----------------
The Validity of the Thyromental Height Test as a Predictor of the Difficult Airway: A Prospective Comparative Study With Interincisor Distance, Thyromental Distance, Sternomental Distance & Modified Mallampati Test

Conditions
-----------------
Difficult Intubation

Intervention / Treatment
-----------------
* Diagnostic Test: Thyromental height test


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: ASA physical status I & II Scheduled for elective surgical procedures under general anesthesia using endotracheal with conventional laryngoscopy Exclusion Criteria: Patients with a body mass index >35 kg/m2. Patients with neuromuscular disorders, craniofacial abnormalities, and abnormal dentition. Patients with airway diseases e.g cancer larynx or tongue, uncooperative patients, those who will need awake intubation and patients who will undergo emergency operations.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Diagnostic Test: Thyromental height test|Assessment of difficult airway|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| validity of the TMHT in prediction of difficult airway in patients undergoing general anesthesia for elective surgeries using area under ROC curve for the TMHT. |  | baseline (before induction of general anesthesia) | 
| Validity of TMHT in comparison with that of Modified Mallampati test (MMT) in prediction of difficult airway by comparing area under ROC curve for both tests. |  | baseline (before induction of general anesthesia) |
Left Ventricular DYsfunction in DiAbetes

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate the prevalence, during the enrolment, of Left Ventricular Dysfunction diastolic and/or systolic in patients with diabetes mellitus type 2 without known or documented heart disease history and recognize its predictive clinical, biohumoral and with non-invasive techniques parameters.

Official Title
-----------------
Left Ventricular DYsfunction in DiAbetes

Conditions
-----------------
Diabetes Mellitus, Type 2, Heart Diseases, Left Ventricular Dysfunction

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: diabetes mellitus type 2 absence of heart disease previously reported age >45 years Informed Consent Exclusion Criteria: presence of heart disease previously reported diabetes type 1 serious systemic disease, with an expected lifetime lower than 2 years no willingness to participate to the screening inadequate compliance to study procedure participation to other study

Ages Eligible for Study
-----------------
Minimum Age: 45 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| No treatment<br>Patients with: diabetes mellitus type 2 absence of heart disease previously reported age >45 years Informed Consent Patients without: presence of heart disease previously reported diabetes type 1 serious systemic disease, with an expected lifetime lower than 2 years no willingness to participate to the screening inadequate compliance to study procedure participation to other study | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Prevalence of Left Ventricular Dysfunction in patients with type II diabetes | To evaluate the prevalence of left ventricular dysfunction (LVD), diastolic or systolic in patients with type II diabetes mellitus in the absence of clinical signs/symptoms of cardiac abnormalities To identify the predictors of LVD | left ventricula dysfunction at enrollment | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Diabetes Mellitus, Type 2, Left Ventricular Dysfunction, Heart Diseases
Arterial Stiffness and Decreased Bone Buffering Capacity in Hemodialysis Patients

Study Overview
=================
Brief Summary
-----------------
Renal patients have an increased risk for cardiovascular complications. There is also increased vascular calcification and bone metabolism is similarly abnormal in patients with chronic kidney disease. In dialysis patients frequent episodes of hypercalcaemia occur. In a healthy bone structure those episodes of hypercalcemia are buffered by the bone. The absence of bone buffering capacity in dialysis patients can be a mechanism for vascular calcifications.

Detailed Description
-----------------
Study hypothesis. Patient with a higher ∆ Calcium (Calcium post - Calcium pre) have a diminished bone buffering capacity indicative for adynamic bone disease compared with patients with smaller ∆ Calcium. This may result in higher extraosseous calcification and higher pulse wave velocity ∆ PTH/∆ Calcium may reflect the sensitivity and density of the calcium receptors; this may reflect parathyroid health

Official Title
-----------------
Arterial Stiffness and Decreased Bone Buffering Capacity in Hemodialysis Patients

Conditions
-----------------
Kidney Disease, Hypercalcemia

Intervention / Treatment
-----------------
* Procedure: high calcium dialysate


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: maintenance hemodialysis patients Exclusion Criteria: dialysis <3 months aortobifemoral graft calcium level predialysis >10.5 mg/dl

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: high calcium dialysate|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| correlation between calcium increase and pulse wave velocity | correlation between calcium increase and pulse wave velocity |  | 
| correlation between calcium change and pth change | correlation between calcium change and pth change |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| correlation between calcium increase and vascular calcifications | correlation between calcium increase and vascular calcifications |  | 
| correlation between calcium change and bone markers | correlation between calcium change and bone markers |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
dialysis, vascular calcification, bone mineralism, arterial stiffness, bone metabolism, chronic kidney disease
Prevalence of Self-medication for Dental Conditions by Parents for Their Children

Study Overview
=================
Brief Summary
-----------------
To evaluate prevalence of self-medication for dental conditions by parents for their children. Self-medications practices.

Detailed Description
-----------------
According to the World Health Organization, self-medication is the act of medicating oneself, either on their own initiative or on the advice of a close person, to treat self-recognized conditions or symptoms without supervision by a healthcare professional. The growth and dissemination of self-medication practice represents a serious global public health issue, with increased risks of adverse drug reactions, non-beneficial drug interactions, drug abuse, and the emergence of drug-resistant pathogens. Parents are the primary caregivers to whom children report their symptoms. But due to the presence of economic and time constraints, some parents seek the practice of self-medication for their children . However, children have a growing body reacting differently to the drugs (need of dose adjustment, choice of the proper route of administration and the need of taking in consideration the pharmacokinetics and pharmacodynamics particularities of medicines) and therefore the inappropriate and unguided use of medications may lead to fatal complications.

Official Title
-----------------
Prevalence of Self-medication for Dental Conditions by Parents for Their Children

Conditions
-----------------
Self-medication for Dental Conditions

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Parents of healthy children up to 10 years. Parents who accept to participate in the study Exclusion Criteria: Guardians other than parents (child's father or mother).

Ages Eligible for Study
-----------------
Minimum Age: 3 Years
Maximum Age: 10 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| prevalence of self-medication | Questionnaire (binary or MSQ questions) | one year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| self-medication practices | Questionnaire (binary or MSQ questions) | one year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Self-medication-drug interactions
Effect of Ketalar to Prevent Postoperative Chronic Pain After Mastectomy

Study Overview
=================
Brief Summary
-----------------
Prevalence of chronic pain after mastectomy is beyond 50% 3 months after surgery. This pain is related to a sensitization of the central nervous system through N-methyl-D-asparate (NMDA) receptors. Ketalar might prevent the occurrence of chronic pain by anti-NMDA properties after mastectomy.

Official Title
-----------------
Effect of Ketalar to Prevent Postoperative Chronic Pain After Mastectomy

Conditions
-----------------
Pain, Breast Cancer

Intervention / Treatment
-----------------
* Drug: ketalar


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Mastectomy in patients 18 to 80 years old Exclusion Criteria: American Society of Anesthesiology (ASA) class >= 3 Renal, heart or hepatic failure Allergy to ketalar Psychiatric disease Chronic antalgic treatment

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: ketalar|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To evaluate the effect of perioperative ketalar on pain intensity 3 months after a mastectomy |  |  | 
| Pain intensity is evaluated by an appropriate questionnaire 1 and 3 months after surgery. |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To evaluate the incidence of chronic pain after mastectomy, the impact on life quality, and the area of hyperalgesia |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Ketalar, NMDA, mastectomy, postoperative chronic pain, Chronic pain after mastectomy for breast cancer
A Pilot Study Of The Effects Of Microcurrent On Three Sleep Surveys

Study Overview
=================
Brief Summary
-----------------
Participants identified as having primary insomnia will be randomly assigned to groups receiving microcurrent stimulation or sham in a double-blind randomized controlled trial. The microcurrent device used is FDA approved for the treatment of insomnia. The hypothesis is that the experimental group will have significantly improved scores on three sleep surveys after treatment while the sham group will not.

Official Title
-----------------
A Pilot Study Of The Effects Of Microcurrent On Three Sleep Surveys

Conditions
-----------------
Primary Insomnia

Intervention / Treatment
-----------------
* Device: Microcurrent
* Device: Microcurrent


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Student, Faculty or Staff Age 18 - 40 Symptoms of primary insomnia Exclusion Criteria: No implanted electric devices No local infection, injury or malignancy No history of seizure or other neurological disorders No current use of prescription or other substances that could effect sleep quality or quantity Pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: MC-E<br>20 minutes of sub-threshold microcurrent 2 hours before bedtime per day for 21 days. | Device: Microcurrent<br>* 20 minutes of sub-threshold microcurrent 2 hours before bedtime per day for 21 days.<br>|
| Placebo Comparator: MC-P<br>Participants will receive a device identical to the active device used in the experimental condition, but which produces no current. | Device: Microcurrent<br>* Participants will receive a device identical to the active device used in the experimental condition, but which produces no current.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pittsburgh Sleep Quality Index (PSQI) |  |  | 
| Epworth Sleepiness Scale |  |  | 
| Insomnia Severity Index |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Primary Insomnia, Microcurrent Therapy, Sleep Surveys